Alkylating agent linked to therapy-related leukemia

January 15, 2013
Alkylating agent linked to therapy-related leukemia
For patients treated for Hodgkin's lymphoma, cumulative doses of alkylating agent is associated with the risk of therapy-related acute myeloid leukemia/myelodysplastic syndrome, according to a study published online Jan. 7 in the Journal of Clinical Oncology.

(HealthDay)—For patients treated for Hodgkin's lymphoma (HL), cumulative doses of alkylating agent (AA) is associated with the risk of therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS), according to a study published online Jan. 7 in the Journal of Clinical Oncology.

Michael Zach Koontz, M.D., from the Stanford University Medical Center in California, and colleagues reviewed the records of 754 patients with HL (treated from 1974 to 2003) with at least five years of follow-up after completing therapy in successive generations of Stanford clinical trials. S studies (1974 to 1980) and C studies (1981 to 1989) utilized extended-field , while G studies (1989 to 2003) utilized involved-field radiotherapy. Primary chemotherapies varied by study.

The researchers found that, in the G studies, the cumulative exposure to AA was substantially lower than in the S and C studies, with a 75 to 83 percent lower dose of nitrogen mustard and omission of procarbazine and . t-AML/MDS developed in 24 patients, 15 following primary chemotherapy and nine after salvage for relapsed HL. G studies had a significantly lower incidence of t-AML/MDS (0.3 percent) compared with the S (5.7 percent) or C (5.2 percent) studies. No t-AML/MDS was seen in G studies after primary therapy. No patient from the G studies developed t-AML-MDS after primary therapy; t-AML/MDA developed in one patient from the G studies following second-line therapy.

"Our data demonstrate the relationship between the cumulative AA dose and t-AML/MDS," the authors write. "The prognosis for t-AML/MDS is dismal, and it is imperative that therapies minimize these risks."

One author disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

No higher risk of acute leukaemia in close relatives

December 15, 2011

(Medical Xpress) -- Parents, siblings and children of patients with the most common form of acute leukemia do not run a higher risk of developing the disease as was once believed, according to a new study from the Swedish ...

Recommended for you

Strange circular DNA may offer new way to detect cancers

July 30, 2015

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.